ProQR update and additional sepofarsen Illuminate trial analyses News update ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial. April 13, 2022